SDMA is more than just a chronic kidney disease biomarker. It is more sensitive and more reliable than creatinine and is an earlier indicator of progressive kidney function loss due to acute or chronic disease. SDMA provides value in wellness testing and in evaluations other than wellness examinations, a topic that will include analysis of a new data set. An increased SDMA can also be an indicator for concurrent diseases that can secondarily impact kidney function and should be investigated. Clinical case examples will be discussed that illustrate the expanded clinical utility of SDMA.

Discussion Topics:

  • Emphasize that traditional diagnostics can miss kidney disease in well and sick patients.
  • Review the studies showing that SDMA increases earlier than creatinine in pets with kidney disease and that SDMA is not impacted by lean muscle mass.
  • Demonstrate how SDMA adds value to blood work performed on dogs and cats presenting for wellness or sick patient, preanesthetic, or recheck examinations.
  • Introduce the Catalyst® SDMA Test and review data supporting its accuracy.
  • Outline what next steps should be taken when SDMA is increased.
  • Discuss the updated clinical utility of SDMA beyond chronic kidney disease (CKD).
  • Review clinical cases illustrating SDMA’s value as an indicator of concurrent diseases.